Live Analyst Rating Changes 40014 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Yale Jen
LAID

Yale Jen

Laidlaw
Wall Street Analyst
★☆☆☆☆
#3207
on 13Foresight · ranked by our own returns
26%
Success Rate
-4.0%
Average Return
6 of 23 calls profitable · -0.9% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 26% of Yale Jen's ratings turned a profit when each position was held for 1 year — averaging -4.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

5 Buy 2 Hold 0 Sell
Yale's Stock Coverage 33 ratings · 2026-10-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
AEON
AEON Biopharma
 Sep 09, 2026 BUY Strong Buy
+526.9% avg upside
3 analysts
$1.80
552.27% Upside
 +16.9% ·
EYPT
EyePoint Pharmaceuticals
 Aug 17, 2026 BUY Strong Buy
+576.3% avg upside
21 analysts
$48.00
1311.72% Upside
 -30.2% ·
NCEL
NewcelX
 Jul 13, 2026 BUY Strong Buy
+479.1% avg upside
4 analysts
$23.00
655.39% Upside
 -23.9% ·
KZIA
Kazia Therapeutics
 Apr 15, 2026 BUY Strong Buy
+193.6% avg upside
8 analysts
$25.00
180.03% Upside
 -7.1% ·
FEMY
Femasys
 Nov 20, 2025 BUY Strong Buy
+3086.3% avg upside
6 analysts
$130.00
6399.98% Upside
 -86.9% ·
NSRX
Nasus Pharma Ltd.
 Sep 29, 2025 BUY Strong Buy
+483.7% avg upside
2 analysts
$22.00
526.78% Upside
 -52.7% ·
VKTX
Viking Therapeutics
 Aug 20, 2025 BUY Strong Buy
+155.7% avg upside
31 analysts
$110.00
285.77% Upside
 +33.8% ·
SNTI
Senti Biosciences
 Jun 06, 2025 BUY Strong Buy
+2663.2% avg upside
7 analysts
$5.00
1490.32% Upside
 -74.9% ·
ALDX
Aldeyra Therapeutics
 Apr 04, 2025 BUY Strong Buy
+1640.4% avg upside
21 analysts
$11.00
1100.51% Upside
 -12.2% ·
NVCT
Nuvectis Pharma
 Mar 17, 2025 BUY Strong Buy
+39.9% avg upside
7 analysts
$19.00
10.03% Downside
 -8.2% ·
LFWD
Lifeward
 Feb 10, 2025 BUY Buy
+12.5% avg upside
8 analysts
$10.00
54.15% Upside
 -70.8% ·
XAIR
Beyond Air
 Nov 12, 2024 BUY Strong Buy
+3788.3% avg upside
11 analysts
$100.00
4344.36% Upside
 · ·
IONS
Ionis Pharmaceuticals
 Oct 08, 2024 BUY Buy
+68.0% avg upside
43 analysts
$68.00
50.15% Upside
 +85.1% ·
CRIS
Curis
 Sep 27, 2024 BUY Strong Buy
+1869.8% avg upside
12 analysts
$20.00
2879.72% Upside
 · ·
ABVX
Abivax SA Sponsored ADR
 Jul 29, 2024 BUY Strong Buy
+53.1% avg upside
16 analysts
$48.00
45.58% Downside
 +491.0% ·
LITS
Lite Strategy
 Jul 23, 2024 HOLD Strong Buy
+766.5% avg upside
13 analysts
 — +69.9% ·
ARCT
Arcturus Therapeutics
 Jul 02, 2024 BUY Buy
+130.3% avg upside
36 analysts
$79.00
474.90% Upside
 -36.6% ·
INAB
IN8bio
 Jun 14, 2024 BUY Buy
+5768.5% avg upside
5 analysts
$225.00
16691.05% Upside
 · ·
AFMDQ
Affimed
 Jun 12, 2024 BUY Buy
+4742021.2% avg upside
16 analysts
$25.00
8333233.24% Upside
 · ·
HLSQ
Tessera Defense and Homeland Security
 May 28, 2024 BUY Hold
+8671.9% avg upside
4 analysts
$25.00
8671.90% Upside
 · ·
CING
Cingulate Inc
 Dec 22, 2023 HOLD Strong Buy
+314.7% avg upside
5 analysts
 — -83.6% ·
EVFM
Evofem Biosciences
 Dec 12, 2023 HOLD Buy
+289457.0% avg upside
8 analysts
 — -89.5% ·
SILO
Silo Pharma
 Aug 28, 2023 BUY Strong Buy
+580.2% avg upside
1 analyst
$10.00
580.23% Upside
 -36.6% ·
TCRT
Alaunos Therapeutics
 Aug 15, 2023 HOLD Buy
+1563.0% avg upside
13 analysts
 — -88.8% ·
ATYR
aTyr Pharma
 Mar 14, 2022 BUY Buy
+3392.6% avg upside
17 analysts
$20.00
8023.47% Upside
 -58.5% ·
ADMA
ADMA Biologics
 Nov 09, 2020 BUY Strong Buy
+5.8% avg upside
15 analysts
$5.63
45.69% Downside
 -21.6% ·
TRAW
Traws Pharma
 Aug 24, 2020 HOLD Buy
+6975.5% avg upside
10 analysts
 — · ·
OPK
Opko Health
 Jul 31, 2020 BUY Buy
+388.2% avg upside
12 analysts
$8.50
516.01% Upside
 -33.2% ·
CARM
Carisma Therapeutics
 Aug 09, 2019 HOLD Hold
+584900.0% avg upside
11 analysts
 — · ·
RKTO
Rocket One
 May 20, 2019 BUY Strong Buy
+1585.5% avg upside
8 analysts
$10.00
1440.04% Upside
 · ·
CNSY
Cerenome
 Nov 15, 2018 BUY Strong Buy
+1353.7% avg upside
11 analysts
$90.00
4563.27% Upside
 · ·
SVRA
Savara
 Sep 27, 2016 HOLD Strong Buy
+77.2% avg upside
17 analysts
 — · ·
IRD
Opus Genetics
 Sep 16, 2014 BUY Strong Buy
+160.5% avg upside
25 analysts
$3.50
24.81% Downside
 · ·
🔒 28 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Yale Jen — Frequently Asked Questions
How accurate are Yale Jen's stock ratings?
Based on the calls 13Foresight could measure, about 26% of Yale's ratings were profitable over a one-year hold, with an average return of -4.0% per rating, or -0.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Yale ranked on 13Foresight?
Yale Jen is currently ranked #3207 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Yale cover?
Yale most recently has ratings on AEON, EYPT, NCEL, KZIA, FEMY, NSRX, VKTX, SNTI, ALDX, NVCT, LFWD, XAIR and 21 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.